Home Featured Page 86

Featured

Latest

Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin Approval

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical, and Increasingly Coordinated

Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future

“If I can’t change my views based on evidence, then why do science at all?” Nora Volkow on Psychedelics

Psychedelic Bulletin #144: Otsuka to Buy Mindset; Responses to FDA Draft...

FILAMENT HEALTH ENTERS LICENSING AGREEMENT WITH RESET PHARMA

BREAKING: Big Pharma Company Otsuka to Acquire Mindset Pharma for CAD...

COMPASS Pathways to participate in upcoming September investor conferences

PT436 – The Power of Sound: The Magic in Live Performances,...

Cybin Set to Acquire British DMT Drug Developer Small Pharma

PT435 – The Federal Right to Try Act, The Farm Bill,...

Sunstone Therapies in Collaboration with the University of Vermont Announces Publication...

GH Research Reports Second Quarter 2023 Financial Results and Provides Business...

PT434 – Kiyumí Retreats, Building Somatic Literacy, and Navigating Group Facilitation...

EDITOR PICKS

Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona...

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin...

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical,...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.